Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FLYER evaluates number of R-CHOP cycles in DLBCL

Poeschel V et al. ASH 2018, Abstract 781

Key clinical point: Four cycles of R-CHOP was noninferior to six cycles in younger patients with favorable-prognosis diffuse large B-cell lymphoma.

Major finding: R-CHOP 4 was noninferior to R-CHOP 6 for the primary progression-free survival endpoint.

Study details: A randomized trial in 588 patients with favorable-prognosis diffuse large B-cell lymphoma.

Disclosures: The study was sponsored by the German High-Grade Non-Hodgkin’s Lymphoma Study Group. Dr. Poeschel reporteed travel grants from Roche and Amgen. Dr. Steensma reported no disclosures relevant to the study.

Read the article here.

Citation:

Poeschel V et al. ASH 2018, Abstract 781.

This Week's Must Reads

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

Must Reads in Aggressive Lymphomas

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6